[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tree-nut-allergies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tree-nut-allergies":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100606053","phase-2-unc-cashew-sublingual-immunotherapy-100606053",false,"NCT07170540","UNC Cashew Sublingual Immunotherapy","Cashew Allergy Study in Children: Assessing Desensitization, Efficacy, and Safety (CASCADES Study)","CASCADES","Inclusion Criteria:\n\n* Age 1-11 years at enrollment\n* Cashew allergy, with allergy defined as:\n* History of clinical reaction to cashew AND cashew-specific IgE \\>\u002F=0.35 kUA\u002FL AND cashew SPT \\>\u002F=3 mm\n* OR if no prior reaction, cashew-specific IgE \\>\u002F=5 kUA\u002FL AND cashew SPT \\>\u002F=3 mm\n* Positive Double-Blind Placebo Controlled Food Challenge (DBCPFC) to 443 mg cumulative cashew at enrollment\n* If female of child-bearing potential, must have a negative urine or serum pregnancy test\n* If female of childbearing potential (defined as females who have reached menarche or who are 12 years or older), must agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods (barrier methods or oral, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy) during the treatment period\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant and\u002For parent\u002Flegal guardian to give written informed consent and\u002For assent or comply with the study protocol\n* History of severe anaphylaxis to cashew defined as neurological compromise or requiring intubation\u002Fmechanical ventilation\n* Known oat, wheat, or glycerin allergy\n* Poorly controlled or severe asthma\u002Fwheezing at screening, defined by at least one of the following criteria:\n* Global Initiative for Asthma (GINA) 2024 criteria for uncontrolled asthma\n* History of 2 or more systemic corticosteroid courses within 6 months of screening or one course of systemic corticosteroids within 3 months of screening to treat asthma\u002Fwheezing\n* Prior intubation\u002Fmechanical ventilation for asthma\u002Fwheezing\n* Hospitalization or overnight Emergency Department (ED) visit for asthma\u002Fwheezing within 6 months of screening\n* Forced expiratory volume in one second (FEV1) \\\u003C80% of predicted or FEV1\u002Fforced vital capacity (FVC) \\\u003C75%, with or without controller medications (for participants \\>\u002F= 6 years and older, able to perform spirometry)\n* Peak expiratory flow rate (PEFR) \\\u003C80% of predicted for participants \\>6 and able to perform peak flow\n* Inhaled corticosteroid (ICS) dosing of \\>500 mcg daily fluticasone (or equivalent ICS)\n* Eosinophilic or other inflammatory (e.g., celiac) gastrointestinal disease\n* Inability to discontinue antihistamines at least 5 half-lives before scheduled SPT and DBPCFC\n* Food immunotherapy such as Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), or Epicutaneous (EPIT) for cashew or pistachio within 6 months of enrollment\n* Monoclonal antibodies such as omalizumab (Xolair), dupilumab (Dupixent), benralizumab (Fasenra), mepolizumab (Nucala), or other immunomodulatory therapy within 6 months of enrollment\n* Currently on dose escalation of environmental allergen immunotherapy (SCIT or SLIT). Individuals on maintenance allergen immunotherapy can be enrolled\n* Participation in any interventional study within the past 3 months\n* Pregnant or breastfeeding\n* Past or current medical condition or clinical significant laboratory abnormality that, in the opinion of the PI, would make the participant unsafe or otherwise unsuitable for participation in the clinical trial","ALL","1 Year","11 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The CASCADES study will investigate the safety and efficacy of sublingual immunotherapy (SLIT) for the treatment of cashew allergy in children ages 1-11 years old. Primary efficacy will be assessed after 18 months of cashew SLIT. Lab studies and an oral food challenge after 6 months of cashew SLIT will help determine how quickly cashew SLIT begins to take effect.",[28,29],"Cashew Nut Allergy","Tree Nut Allergies",[31,32,33,34,35],"cashew allergy","tree nut allergy","food allergy","sublingual immunotherapy","SLIT","NOT_YET_RECRUITING","2026-04-13",{"date":39,"type":40},"2026-04-14","ACTUAL",{"date":42,"type":22},"2026-06",{"date":44,"type":22},"2028-12",{"name":46,"class":47},"University of North Carolina, Chapel Hill","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100223945","blood-samples-for-the-study-of-peanut-tree-nut-and-other-food-allergies-100223945","NCT02192866","Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies","Inclusion Criteria:\n\nThis protocol is to draw blood for a variety of related studies of food allergy. For this reason, we will list each group of subjects and the inclusion criteria for that group.\n\n1. De-identified sera or plasma from patients who have undergone Oral ImmunoTherapy (OIT) for peanut allergy. These samples already exist.\n\n   * Inclusion criteria:\n\n     1. patients have been enrolled in a controlled trial of OIT for peanuts, and had at least one oral challenge.\n     2. Age 1-75.\n2. De-identified samples from patients who are undergoing clinically indicated food challenges for peanut allergy.\n\n   * Inclusion criteria:\n\n     1. concern regarding possible allergy to peanuts,\n     2. age 1-75,\n     3. plan to undergo a clinically indicated challenge with peanuts.\n3. Patients with peanut allergy.\n\n   * Inclusion criteria:\n\n     1. excellent history of a systemic reaction to peanuts,\n     2. age 6-75.\n4. Patients with other food allergies (especially tree nuts).\n\n   * Inclusion criteria:\n\n     1. excellent history of a systemic reaction to tree nuts or other foods,\n     2. age 6-75.\n5. Normal controls.\n\n   * Inclusion criteria:\n\n     1. no known food allergies,\n     2. recent ingestion of peanuts without difficulty, and\n     3. age 6-75.\n\nExclusion Criteria:\n\n1. Any known significant medical or psychiatric diagnosis\n2. Use of an investigational drug within 30 days\n3. Use of omalizumab (anti-IgE; Xolair) within 6 months",true,"75 Years",{"count":58,"type":22},270,"OBSERVATIONAL","Food allergies are now a major problem. These experiments involve getting blood from people with food allergies and from people without food allergies. The blood collected will be used to answer questions and find information about peanut and other food allergies.\n\nSamples will come from:\n\n* People signed up by the investigators at the University of Colorado Denver\n* University of North Carolina, Massachusetts General Hospital, Children's Hospital of Colorado and the Immune Tolerance Network (Benaroya Research Institute) where people have been treated for peanut allergies\n* University of North Carolina, Massachusetts General Hospital, National Jewish Health and The Children's Hospital in Denver where people have taken part or will take part in clinically indicated oral food challenges.\n\nBlood and health histories from the University of North Carolina, Massachusetts General Hospital, National Jewish Health, The Children's Hospital and the Immune Tolerance Network will not have personal information linked.\n\nThe specific aims of this experiment are:\n\n1. Come up with a lab test that will predict how bad an allergic reaction will be to peanuts.\n2. Find out what part of a peanut causes allergic reactions.\n3. Come up with preventions that can block peanut allergies.\n4. Find the strongest proteins in walnuts.",[62,29,63],"Peanut Allergies","Other Food Allergies","RECRUITING","2022-12-14",{"date":67,"type":40},"2022-12-19",{"date":69,"type":40},"2014-02",{"date":71,"type":22},"2030-12",{"name":73,"class":47},"University of Colorado, Denver"]